[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"periodontitis-stage-iii\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:periodontitis-stage-iii":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,79,110,130],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100590437","comparative-effects-of-two-oral-antiseptics-used-as-an-adjuvant-in-the-treatment-of-periodontitis-100590437",false,"NCT06967402","Comparative Effects of Two Oral Antiseptics Used as an Adjuvant in the Treatment of Periodontitis","Comparative Clinical Efficacy and Microbiological Effects of Two Oral Antiseptics Used as an Adjuvant in the Treatment of Severe Periodontitis","Inclusion Criteria:\n\n* Consenting patients with at least 6 evaluable teeth in each quadrant, including minimum 1 molar and 1 premolar.\n* Generalized stage II-III periodontitis patients.\n* Baseline BOP \\> 25%.\n* No known allergy or adverse effects to CHX or CPC\n* Non-smokers, non-orthodontic patients, no concurrent or past antibiotics\u002Fmedication known to affect periodontal status (i.e. calcium antagonists, phenytoin)\u002Fanti-inflammatory therapy (i.e. NASIDs) in the last 3 months, pregnant\u002Fbreastfeeding, compliance to study procedures.\n* ASA class I-II patients.\n* Either non-diabetic or with controlled diabetes (HbA1C\\\u003C7).\n* Normal\u002FElevated blood pressure (AHA - Systolic \\\u003C130mmHg; Diastolic \\\u003C80mmHg).\n* No radiation\u002Fchemotherapy in the past 5 years\n* No immunosuppression including drug induced immunosuppression.\n* No participation in other clinical studies in the last 4 weeks.\n* No administration of CHX or CPC in the last 3 months\n* No periodontal treatment in the last 3 months.\n\nExclusion Criteria:\n\n* Unable to provide written consent.\n* Non-compliant study procedures.\n* Patients with medical (including psychiatric) and pharmacotherapeutic histories that, in the investigator's opinion, may compromise the protocol.\n* Patients requiring antibiotics prophylaxis for dental procedures.\n* Patients with self-reported pregnancy or patients who are breastfeeding.\n* Patients with history of use of systemic antibiotics, in combination with any form of periodontal treatment, within the past 3 months.\n* Patients with uncontrolled endocrine disease.\n* Patients who are not compliant with the review protocol, leading to deviation of more than 1 week.\n* Patients requiring the admission of systemic antibiotics, in combination with any form of dental treatment, during the study period.","ALL","18 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","The focus of this study is on two types of mouthwashes - one containing a chlorhexidine (CHX) at 0.2% (CHX), and the other one containing CHX at a lower concentration of 0.12% with cetylpyridinium chloride (CPC). Both mouthwashes are used to help in the treatment of gum disease. CHX has been known for a long time for its effectiveness against plaque and mouth inflammation. It could inhibit and even kill them. However higher concentrations of CHX comes with unwanted side effect including altered taste, teeth staining and irritation in the mouth. Interestingly, these side effects seem to occur less frequently when a lower concentration CHX solution is used. CPC also combats bacteria by adhering quickly to the surfaces inside your mouth, although it has less substantivity than CHX, it has been shown to reduce plaque and gum inflammation effectively, and it typically causes fewer side effects than CHX. We hypothesize that this new formulation of CHX 0.12%+CPC mouthwash is non-inferior to CHX 0.2% in terms of its anti-plaque and anti-inflammatory properties while presenting with less side effects after 21 days of use. Microbiological samples and fluids from periodontal pockets will be collected before and after treatment for analysis of microbiological effects.",[26,27,28],"Periodontitis","Periodontitis Stage II","Periodontitis Stage III",[30,31,32,26,33,34,35],"Mouthwash","Chlorhexidine","CPC","Mouthrinse","cetylpyridinium chloride","Oral antiseptic","RECRUITING","2026-06-21",{"date":39,"type":40},"2026-06-23","ACTUAL",{"date":42,"type":40},"2025-11-20",{"date":44,"type":20},"2027-12-31",{"name":46,"class":47},"The University of Hong Kong","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":75,"leadSponsor":77,"locationsCount":48},"100639325","surfactant-protein-d-levels-in-gcf-before-and-after-minst-in-periodontitis-100639325","NCT07599657","Surfactant Protein D Levels in GCF Before and After MINST in Periodontitis","Evaluation of Surfactant Protein D (SP-D) Levels in the GCF of Periodontitis Patients Associated With the Endpoints After Minimally Invasive Non-surgical Periodontal Therapy: A Before and After Study","Inclusion Criteria:\n\n* Male and female participants aged 18 years or older.\n* Diagnosis of periodontitis, classified as stage II or stage III according to the 2018 classification system.\n* Presence of at least one tooth with probing pocket depth (PPD) of 5 mm or more, clinical attachment loss (CAL), and radiographic evidence of bone loss.\n* Presence of at least one intrabony defect with a radiographic intrabony component measuring 3 mm or more.\n\nExclusion Criteria:\n\n* Current smokers or individuals with a history of smoking within the past year.\n* Pregnant or lactating women.\n* Use of systemic antibiotics or anti-inflammatory medications within the last 3 months.\n* Known allergy to any materials or agents used during periodontal therapy.",{"count":57,"type":20},18,[23],"This study will evaluate changes in Surfactant Protein D (SP-D) levels in gingival crevicular fluid (GCF) of patients with periodontitis before and after minimally invasive non-surgical periodontal therapy (MINST).\n\nParticipants diagnosed with stage II or III periodontitis will receive minimally invasive non-surgical periodontal treatment. GCF samples will be collected at baseline and 6 months after treatment, and SP-D levels will be measured using enzyme-linked immunosorbent assay (ELISA).\n\nThe study will also assess clinical periodontal outcomes, including full-mouth plaque score, full-mouth bleeding score, probing pocket depth, clinical attachment level, gingival recession, and patient satisfaction. Each participant will serve as their own control by comparing baseline values with 6-month post-treatment values.",[26,27,28],[62,63,64,65,66,67,68,26,69,70],"Surfactant Protein D","Gingival Crevicular Fluid","ELISA","Periodontal Biomarker","Non-Surgical Periodontal Therapy","MINST","Minimally Invasive Non-Surgical Periodontal Therapy","GCF","SP-D","2026-05-14",{"date":73,"type":40},"2026-05-20",{"date":71,"type":20},{"date":76,"type":20},"2027-02-01",{"name":78,"class":47},"Cairo University",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":21,"phases":89,"briefSummary":90,"conditions":91,"keywords":95,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":4},"100639400","polynucleotides-and-hyaluronic-acid-vs-enamel-matrix-proteins-in-the-treatment-of-intrabony-defects-100639400","NCT07589959","Polynucleotides and Hyaluronic Acid vs Enamel Matrix Proteins in the Treatment of Intrabony Defects","Polynucleotides and Hyaluronic Acid vs Enamel Matrix Derivative Proteins in the Treatment of Intrabony Defects: A Randomized Controlled Clinical Trial","PN-HAVSEMPIND","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Non-smokers or light smokers (fewer than 10 cigarettes per day)\n* No diabetes or well-controlled diabetes\n* At least one infrabony periodontal defect ≥ 3 mm in depth\n* Periodontal pocket depth ≥ 6 mm at baseline (after initial treatment)\n* Full-mouth plaque and bleeding scores ≤ 20%, ≤15% at re-evaluation\n* Ability and willingness to attend follow-up visits for 1, 3, and 5 years\n* Teeth included in the study must be healthy from an endodontic point of view or properly root-treated\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n* Patients with weakened immune systems or significant systemic diseases\n* Heavy smokers (more than 10 cigarettes per day)\n* Full-mouth plaque or bleeding scores \\>20%, \\>15%\n* Current alcohol or drug abuse\n* Patients who have received periodontal treatment within the last 6 months\n* Patients unwilling or unable to attend follow-up visits required for the study",{"count":88,"type":20},40,[23],"The goal of this clinical trial is to compare two periodontal regenerative treatments in adults with Stage III or IV periodontitis and infrabony periodontal defects ≥3 mm.\n\nThe study aims to determine whether hyaluronic acid and polynucleotides (Regenfast®) combined with bovine bone graft material (Bio-Oss®) provides similar or improved periodontal regeneration compared with enamel matrix derivative proteins (Emdogain®) combined with Bio-Oss®.\n\nResearchers will evaluate:\n\n* Periodontal healing and bone regeneration\n* Changes in probing depth, clinical attachment level, gingival recession, and tooth mobility\n* Radiographic bone fill\n* Survival of treated teeth after 1, 3, and 5 years\n\nParticipants will:\n\n* Receive initial periodontal treatment and oral hygiene instruction\n* Undergo clinical and radiographic evaluation\n* Receive minimally invasive periodontal regenerative surgery under local anesthesia\n* Be randomly assigned to receive either Regenfast® + Bio-Oss® or Emdogain® + Bio-Oss®\n* Attend follow-up visits with periodontal examinations and radiographs over 5 years",[92,93,28,94],"Periodontal Bone Loss","Periodontal Defect","Periodontitis Stage IV",[96,97,98,99],"Infrabony Periodontal Defects","Polynucleotides","Hyaluronic Acid","Enamel Matrix Proteins","NOT_YET_RECRUITING","2026-05-11",{"date":103,"type":40},"2026-05-15",{"date":105,"type":20},"2026-05",{"date":107,"type":20},"2031-07-30",{"name":109,"class":47},"Shashi Dadlani",{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":116,"targetDuration":118,"studyType":119,"phases":4,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":126,"leadSponsor":128,"locationsCount":4},"100631789","development-and-validation-of-the-periodontal-map-derived-from-ios-and-cbct-registration-for-diagnosis-and-treatment-planning-in-moderate-to-severe-periodontitis-100631789","NCT07505251","Development and Validation of the Periodontal Map Derived From IOS and CBCT Registration for Diagnosis and Treatment Planning in Moderate-to-severe Periodontitis","Inclusion Criteria:\n\n1. Aged ≥ 18 years.\n2. Diagnosed with Stage II-IV periodontitis according to the 2018 Classification of Periodontal Diseases.\n3. Presence of at least one tooth requiring periodontal surgery (including open flap debridement or regenerative surgery) due to periodontitis, where the intra-bony defect can be exposed intra-operatively for measurement.\n4. Voluntary participation and provision of written informed consent.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women.\n2. Presence of uncontrolled systemic diseases that significantly affect surgery or tissue healing, such as uncontrolled diabetes mellitus or immunodeficiency.\n3. History of head and neck radiotherapy.\n4. Inability to cooperate with the required study examinations.",{"count":117,"type":20},80,"1 Day","OBSERVATIONAL","This prospective diagnostic study aims to validate the clinical utility of a \"Periodontal Panoramic Map\" generated by the PerioAI V2.0 system, an artificial intelligence-based platform that integrates intraoral scans and cone-beam CT data, for preoperative diagnosis and surgical planning in patients with moderate to severe periodontitis (Stage II-IV). Current clinical standards-manual probing and two-dimensional radiography-have inherent limitations in accurately visualizing complex three-dimensional bone defect morphology, leading to potential underestimation of disease severity and suboptimal surgical outcomes. Building upon our team's previously published high-precision PerioAI V1.0 system, this study will enroll 80 patients requiring periodontal surgery. Preoperative intraoral scans and cone-beam CT images will be acquired as part of routine care, and the PerioAI V2.0 system will automatically generate a \"Periodontal Panoramic Map\" with intelligent outputs including probing depth, clinical attachment loss, bone defect morphology classification, furcation involvement grading, and automated measurements of key parameters such as intra-bony defect depth and width. These automated diagnostic results will be compared against the gold standard of full mouth clinical examination and intra-operative direct measurements and observations obtained during periodontal surgery under strict blinded conditions. The primary outcome measures are the accuracy of bone defect morphology classification and the agreement between automated and intra-operative linear measurements assessed by intraclass correlation coefficients and Bland-Altman analysis. Secondary outcomes include accuracy of probing depth, clinical attachment loss, periodontitis staging and grading, furcation involvement grading and treatment planning. This study will provide critical evidence supporting the paradigm shift in periodontal surgery from experience-dependent assessment to data-driven precision medicine, ultimately offering clinicians an intuitive, quantitative, and three-dimensional visualization tool for optimized surgical decision-making.",[27,28,94],"2026-03-26",{"date":124,"type":40},"2026-04-01",{"date":124,"type":20},{"date":127,"type":20},"2028-12-31",{"name":129,"class":47},"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":21,"phases":140,"briefSummary":142,"conditions":143,"keywords":150,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":48},"100615542","phase-2-3-month-clinical-trial-of-liquid-s-prf-in-periodontal-debridement-for-periodontitis-stages-ii-iv-100615542","NCT07293962","3-Month Clinical Trial of Liquid S-PRF in Periodontal Debridement for Periodontitis Stages II-IV","Liquid S-Platelet Rich Fibrin as a Potential Adjunct in Conservative Closed Periodontal Debridement for Periodontitis Stages II-IV: A Randomized, Split-mouth, 3-month Clinical Trial","Inclusion Criteria:\n\n* Have at least 20 teeth,\n* American Society of Anesthesiology class I or II\n* Periodontitis stages II-IV\n* Bilateral sites of deep periodontal pockets ≥5 mm\n\nExclusion Criteria:\n\n* Limited mouth opening or symptomatic temporomandibular joint disorder\n* Inability to tolerate extended long periodontal treatment and\u002For hyperactive gag reflex\n* Current or former smoker or vape user\n* Pregnant and\u002For breastfeeding\n* Having diabetes mellitus type I or II\n* Having bleeding disorder or is on anticoagulants\n* Underwent periodontal treatment and\u002For surgery in past 6 months prior\n* Undergoing orthodontic therapy, or completed in past 3 months prior\n* On or had anti-inflammatory drug(s) in past 3 months prior\n* On or had antibiotic(s) in past 3 months prior\n* Having autoimmune disorder\n* On or had immunosuppressant drug(s) in past 3 months prior\n* Undergoing or underwent radio- and\u002For chemo-therapy","65 Years",{"count":139,"type":20},14,[141],"PHASE2","What is the purpose of this study? This study is to investigate the effect of a processed blood product in healing after treatment for gum disease. In addition to scaling \\& root debridement (deep cleaning) that is the standard treatment for periodontitis, this study will test the effectiveness of patient's processed blood in improving healing of diseased gums.\n\nWhat are the procedures to be followed? First, all patients will undergo dental check-up and X-ray imaging for suitability as a participant for the project. For participants who are eligible and included into study, upper \\& lower jaws models will be made, and each will be given oral care kit \\& instructions. The next appointment will be given for scaling \\& root debridement with local numbing agent in one day. Towards the end of the treatment, a small amount (20 mℓ) of blood will be collected and spun to produce liquid platelet-rich fibrin that is then used to flush the treated gum pockets in half of the mouth. For the treated gum pockets in the opposite half of the mouth, sterile salt water (saline) will be used instead for comparison. Then, follow-up appointments are at monthly intervals until 3 months.\n\nWho should enter the study? Symptoms of gum disease include bleeding and\u002For receding gums, tooth\u002Fteeth appearing longer or feeling shaky\u002Floose\u002Fweak, formation of large amount of calculus and\u002For black\u002Fempty space between teeth, frequent\u002Frecurrent gum swelling\u002Fpus, and\u002For bad breath.",[27,28,144,26,145,146,147,148,149],"Periodontitis (Stage 3)","Periodontitis Chronic Localized Slight","Periodontitis Chronic Generalized Moderate","Periodontitis Chronic Generalized Severe","Periodontitis, Adult","Periodontitis, Chronic",[151,152,153,154,155,156,157,158,159,160,161,162],"periodontal treatment","periodontitis","platelet concentrates","platelet-rich fibrin","nonsurgical","clinical trial","periodontal","nonsurgical periodontal debridement","dental scaling","periodontal diseases","periodontal debridement","nonsurgical periodontal treatment","2025-12-07",{"date":165,"type":40},"2025-12-19",{"date":167,"type":40},"2024-04-01",{"date":169,"type":20},"2026-03",{"name":171,"class":47},"Mahsa University"]